CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.72B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.51: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
38.47BCNY5.72B · vs all stocks (USD)
Revenue (TTM)
2.72BCNY405.10M · vs all stocks (USD)
Profit Margin
-24.26%vs Biotechnology peers
Beta
0.5840xvs all stocks
52-Week Change
-18.40%vs all stocks
Market Capitalization
38.47BCNY5.72B · vs all stocks (USD)
Enterprise Value
39.87BCNY5.93B · vs all stocks (USD)
Forward P/E
-147.67xvs Biotechnology peers
Price to Sales (TTM)
15.46xvs Biotechnology peers
Price to Book (MRQ)
7.14xvs Biotechnology peers
Enterprise to Revenue
14.64xvs Biotechnology peers
Enterprise to EBITDA
-82.25xvs Biotechnology peers
Gross Margin
74.66%vs Biotechnology peers
Profit Margin
-24.26%vs Biotechnology peers
Operating Margin
-12.69%vs Biotechnology peers
Return on Assets (TTM)
-3.70%vs Biotechnology peers
Return on Equity (TTM)
-13.49%vs Biotechnology peers
Revenue (TTM)
2.72BCNY405.10M · vs all stocks (USD)
Revenue per Share (TTM)
2.67CNYUpdated Aug 21, 2026Quarterly Revenue Growth
45.10%vs Biotechnology peers
Gross Profit (TTM)
2.14BCNY318.25M · vs all stocks (USD)
EBITDA (TTM)
-484.78MCNY-72.09M · vs all stocks (USD)
Net Income (TTM)
-660.86MCNY-98.28M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
58.83%vs Biotechnology peers
Operating Cash Flow (TTM)
-437.39MCNY-65.04M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.16BCNY-173.16M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
26.16MCNYFY2025 · Dec 31, 2025Revenue
2.50BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
522.76MCNYFY2025 · Dec 31, 2025Gross Profit
1.98BCNYFY2025 · Dec 31, 2025Operating Income
-925.10MCNY-137.57M · vs all stocks (USD)
Pre-tax Income
-986.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-13.88MCNYFY2025 · Dec 31, 2025Net Income
-972.69MCNYFY2025 · Dec 31, 2025EBIT
-911.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-774.30MCNYFY2025 · Dec 31, 2025Research & Development
1.38BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.57BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.89MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
74.77MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.01BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.01BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
131.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-768.45MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.54BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.59BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-986.57MCNYFY2025 · Dec 31, 2025Stock-based Compensation
77.15MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-10.93MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.10MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
135.81MCNYFY2025 · Dec 31, 2025Capital Expenditures
-768.27MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-26.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-369.71MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.77BCNYFY2025 · Dec 31, 2025Sale of Investments
2.28BCNYFY2025 · Dec 31, 2025Other Investing Activity
5.31MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.62BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.58BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.40BCNYFY2025 · Dec 31, 2025Common Stock Repurchase
0.00CNYFY2025 · Dec 31, 2025Other Financing Charges
241.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
2.37BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.03BSharesUpdated Aug 21, 2026Float Shares
737.40MSharesUpdated Aug 21, 2026% Held by Insiders
31.00%vs all stocks
% Held by Institutions
17.71%vs all stocks
Total Cash (MRQ)
4.56BCNY678.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.45CNYUpdated Aug 21, 2026Total Debt (MRQ)
5.98BCNY888.61M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9812xvs Biotechnology peers
Current Ratio (MRQ)
2.14xvs Biotechnology peers
Book Value per Share (MRQ)
5.75CNYUpdated Aug 21, 2026Total Assets
12.40BCNY1.84B · vs all stocks (USD)
Total Current Assets
4.46BCNYFY2025 · Dec 31, 2025Total Liabilities
6.33BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.94BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
3.51BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.81BCNYFY2025 · Dec 31, 2025Cash
2.59BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.59BCNYFY2025 · Dec 31, 2025Other Short-term Investments
600.78MCNYFY2025 · Dec 31, 2025Accounts Receivable
506.44MCNYFY2025 · Dec 31, 2025Inventory
573.11MCNYFY2025 · Dec 31, 2025Accounts Payable
1.46BCNYFY2025 · Dec 31, 2025Short-term Debt
1.29BCNYFY2025 · Dec 31, 2025Long-term Debt
2.85BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.03BCNYFY2025 · Dec 31, 2025Retained Earnings
-11.16BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.07BCNY903.15M · vs all stocks (USD)
Treasury Stock
30.89MCNYFY2025 · Dec 31, 202552-Week Low
28.10CNYUpdated Aug 21, 202652-Week High
51.40CNYUpdated Aug 21, 202652-Week Change
-18.40%vs all stocks
Beta
0.5840xvs all stocks
50-Day MA
35.47CNYUpdated Aug 21, 2026200-Day MA
36.04CNYUpdated Aug 21, 2026Avg 10-Day Volume
25.71MSharesUpdated Aug 21, 2026Avg 30-Day Volume
20.61MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.8400CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.75Profit Margin: -0.24
Financial Health
Altman Z-Score 2.51: grey zoneSignificant
Altman Z-Score: 2.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.72B, above the global median of $1.18BNotable
Market cap (USD): 5,720,914,595.25Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
HBL Engineering Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
HDFC Asset Management Co. Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated